Holen Sie sich die Stockscreener-App
3.17
1.55%
-0.05
Handel nachbörslich:
3.15
-0.02
-0.63%
Schlusskurs vom Vortag:
$3.22
Offen:
$3.22
24-Stunden-Volumen:
112.89K
Relative Volume:
0.59
Marktkapitalisierung:
$271.97M
Einnahmen:
$351.37M
Nettoeinkommen (Verlust:
$-135.96M
KGV:
-2.4766
EPS:
-1.28
Netto-Cashflow:
$-85.40M
1W Leistung:
-5.65%
1M Leistung:
-17.02%
6M Leistung:
-13.15%
1J Leistung:
+4.62%
1-Tages-Spanne:
$3.155
$3.315
1-Wochen-Bereich:
$3.155
$3.475
52-Wochen-Spanne:
$2.765
$4.60
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Firmenname
Atea Pharmaceuticals Inc
Sektor
Branche
Telefon
857-204-8109
Adresse
225 FRANKLIN STREET, BOSTON
Vergleichen Sie AVIR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| AVIR | 3.17 | 271.97M | 351.37M | -135.96M | -85.40M | -1.28 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-24 | Eingeleitet | JP Morgan | Overweight |
| 2020-11-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Atea Pharmaceuticals Inc Aktie (AVIR) Neueste Nachrichten
Atea Pharmaceuticals Presents Multiple New Datasets - GlobeNewswire
Atea Pharmaceuticals Presents Multiple New Datasets Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024 - GlobeNewswire Inc.
FMR LLC Increases Stake in Atea Pharmaceuticals Inc - GuruFocus.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) is BML Capital Management LLC's 3rd Largest Position - MarketBeat
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q3 2024 Earnings Call Transcript - Insider Monkey
Atea Pharmaceuticals Advances in HCV Treatment Development - TipRanks
Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Atea Reports $31.2M Loss, Exits COVID Program Despite Strong HCV Pipeline Results | AVIR Stock News - StockTitan
AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday - MarketBeat
Atea Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call on November 7, 2024 - The Manila Times
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD's The Liver Meeting 2024 - The Manila Times
Atea Pharmaceuticals to Present New Data Supporting the - GlobeNewswire
Atea Pharmaceuticals to Present New Data Supporting the Combination of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at AASLD’s The Liver Meeting 2024 - StockTitan
SG Americas Securities LLC Increases Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Morgan Stanley Upgrades Atea Pharmaceuticals (AVIR) - MSN
Atea Pharmaceuticals Leads The Charge In US Penny Stocks Spotlight - Simply Wall St
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
Dimensional Fund Advisors LP Buys 211,428 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
182,326 Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Purchased by Marshall Wace LLP - MarketBeat
Atea Pharmaceuticals (AVIR) Loses -8.01% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Almitas Capital LLC Invests $4.27 Million in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Metrics That Matter About Atea Pharmaceuticals Inc (NASDAQ: AVIR) - Stocks Register
Jean-Pierre Sommadossi Sells 33,941 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Stock - MarketBeat
Atea Pharmaceuticals CEO sells over $234k in company stock - Investing.com India
Atea Pharmaceuticals CEO sells over $234k in company stock By Investing.com - Investing.com UK
Q3 2024 EPS Estimates for Atea Pharmaceuticals, Inc. Lifted by Analyst (NASDAQ:AVIR) - MarketBeat
Data from Merck, Daiichi could support first approval for HER3 ADC - BioCentury
Atea Pharmaceuticals (NASDAQ:AVIR) & SELLAS Life Sciences Group (NASDAQ:SLS) Critical Analysis - Defense World
Short Interest in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Rises By 13.7% - MarketBeat
Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus - AOL
AVIR’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
Atea Pharmaceuticals Shares Fall on Covid-19 Treatment Trial Result - MarketWatch
Atea stock drops as COVID-19 therapy fails in late-stage trial - MSN
Atea stock falls after setback to COVID-19 drug (NASDAQ:AVIR) - Seeking Alpha
Atea Pharmaceuticals reports Phase 3 trial miss for COVID-19 drug - Investing.com
Atea Pharmaceuticals Trial of Covid-19 Treatment Bemnifosbuvir Fails to Meet Primary Endpoint - MarketWatch
Atea Pharmaceuticals Provides Update on Global Phase 3 - GlobeNewswire
Atea Pharmaceuticals Provides Update on Global Phase 3 Rise-3 Trial Evaluating Bemnifosbuvir for Treatment of COVID-19 - Marketscreener.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Acadian Asset Management LLC - Defense World
New Data on Bemnifosbuvir's Progress in COVID-19 and HCV Trials - Contagionlive.com
Atea Pharmaceuticals advances antiviral drug study - Investing.com
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by SG Americas Securities LLC - Defense World
Atea Pharmaceuticals Announces Publication of Additional Data Further Highlighting Bemnifosbuvir’s Metabolic Activation Pathway - ForexTV.com
Atea Pharmaceuticals Announces Publication of Additional - GlobeNewswire
California State Teachers Retirement System Cuts Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Finanzdaten der Atea Pharmaceuticals Inc-Aktie (AVIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):